Ngan H Y, Cheung A N, Liu S S, Cheng D K, Ng T Y, Wong L C
Department of Obstetrics and Gynaecology, Queen Mary Hospital, University of Hong Kong, Hong Kong.
Tumour Biol. 2001 May-Jun;22(3):176-83. doi: 10.1159/000050613.
The aim of this study is to assess the expression of epidermal growth factor receptor (EGFR) and c-erbB2 and their correlation with human papillomavirus (HPV) status and prognosis in squamous cell carcinoma of the cervix. The expression of EGFR and c-erbB2 was studied at the protein level using the immunohistochemical (IHC) staining method, at the RNA level using the ribonuclease protection assay and at the DNA level using Southern blot and hybridization method. One hundred and one patients with squamous cell carcinoma of the cervix were recruited. Fifty-one patients were of stage 1B/2A and 50 patients were of stage 2B and above. Positive IHC stainings of EGFR and c-erbB2 proteins were found in 74.2 and 19.8% of cases, respectively. DNA amplifications of EGFR and c-erbB2 genes were detected in 35.4 and 17.2%, respectively. Of the patients showing positive EGFR and c-erbB2 staining, only 39.2 and 25%, respectively, showed DNA amplifications. RNA overexpression of EGFR or c-erbB2 was only detected in 2% of cervical cancers and was associated with positive staining and DNA amplifications. HPV was detected in 79.2% of the cases by HPV consensus primers L1, in 57.4% for HPV 16 and 27.7% for HPV 18. The abnormal expression of EGFR and c-erbB2 had no correlation with HPV detection and had no prognostic significance on survival.
本研究旨在评估表皮生长因子受体（EGFR）和c-erbB2的表达及其与子宫颈鳞状细胞癌中人乳头瘤病毒（HPV）状态和预后的相关性。采用免疫组织化学（IHC）染色法在蛋白质水平研究EGFR和c-erbB2的表达，采用核糖核酸酶保护试验在RNA水平研究，采用Southern印迹和杂交法在DNA水平研究。招募了101例子宫颈鳞状细胞癌患者。51例为1B/2A期，50例为2B期及以上。EGFR和c-erbB2蛋白的IHC阳性染色分别在74.2%和19.8%的病例中发现。EGFR和c-erbB2基因的DNA扩增分别在35.4%和17.2%的病例中检测到。在EGFR和c-erbB2染色阳性的患者中，分别只有39.2%和25%显示DNA扩增。EGFR或c-erbB2的RNA过表达仅在2%的宫颈癌中检测到，且与阳性染色和DNA扩增相关。通过HPV通用引物L1在79.2%的病例中检测到HPV，HPV 16为57.4%，HPV 18为27.7%。EGFR和c-erbB2的异常表达与HPV检测无关，对生存无预后意义。
